BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 28, 2015
View Archived Issues
Valeant to acquire Commonwealth Laboratories' business in U.S. and Canada
Read More
Scynexis sells services business, focuses on SCY-078
Read More
Novel orally active Chk1 inhibitor boosts combination therapies for lung and pancreatic cancer
Read More
Gene therapy with viral vectors carrying Tmc genes, a promising approach for genetic deafness
Read More
Caladrius Biosciences secures NIH grant to develop 3D retinal cell implants
Read More
Bone marrow-derived mesenchymal stromal cell therapy beneficial in severe ischemic heart failure
Read More
Therapure Biopharma receives funding for manufacture of plasma proteins
Read More
Astellas partners with AIST in virtual drug discovery
Read More
FDA grants orphan drug designation to Ziopharm's Ad-RTS-hIL-12 + veledimex for malignant glioma
Read More
Bristol-Myers Squibb offers overview of second quarter 2015
Read More
World Hepatitis Day 2015: New management recommendations and new treatments
Read More
EMA grants accelerated assessment to MAA for elotuzumab in MM
Read More
Medivation discloses TGF-beta signaling inhibitors
Read More
Rhizen patents glutaminase inhibitors
Read More
Bristol-Myers Squibb introduces ROR-gamma modulators
Read More
Purdue Pharma divulges morphinan analgesics
Read More
Beijing Institute of Pharmacology and Toxicology discloses new analgesics
Read More
TapImmune exercises option agreement for folate receptor alpha vaccine technology
Read More
Alnylam starts phase I/II trial of RNAi targeting alpha-1 antitrypsin
Read More
Teva to acquire Allergan generics; withdraws offer for Mylan
Read More
Epratuzumab misses primary endpoints in two phase III SLE trials
Read More
Clinical benefit seen with trofinetide in phase II Rett's syndrome study
Read More
FDA clears FibroGen to begin phase II trial of FG-3019 for DMD
Read More
EMA committee recommends approval of Cresemba for invasive aspergillosis and mucormycosis
Read More
Obizur recommended for approval in Europe for acquired hemophilia A
Read More
EMA committee hands down positive opinion for Zerbaxa
Read More